The purpose of this study was to evaluate the efficacy and tolerance of recombinant human interferon gamma (rIFN-gamma) as second-line treatment in patients with persistent disease at second-look laparotomy.

Pujade Lauraine, E., Guastalla, J., Colombo, N., Devillier, P., François, E., Fumoleau, P., et al. (1996). Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. JOURNAL OF CLINICAL ONCOLOGY, 14(2), 343-350.

Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy

COLOMBO, NICOLETTA;
1996

Abstract

The purpose of this study was to evaluate the efficacy and tolerance of recombinant human interferon gamma (rIFN-gamma) as second-line treatment in patients with persistent disease at second-look laparotomy.
Articolo in rivista - Articolo scientifico
Prognosis; Reoperation; Survival Rate; Middle Aged; Female; Neoplasm, Residual; Interferon-gamma; Humans; Age Factors; Antineoplastic Agents; Ovarian Neoplasms; Recombinant Proteins; Aged; Chemotherapy, Adjuvant; Adult; Laparotomy
English
1996
14
2
343
350
none
Pujade Lauraine, E., Guastalla, J., Colombo, N., Devillier, P., François, E., Fumoleau, P., et al. (1996). Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. JOURNAL OF CLINICAL ONCOLOGY, 14(2), 343-350.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/27507
Citazioni
  • Scopus 161
  • ???jsp.display-item.citation.isi??? 134
Social impact